Cancer prevalence is rising globally. Radiopharmaceuticals and Theranostics offer precise, targeted diagnostic and therapeutic solutions for safer, more tolerable oncology therapies. Implementing a successful radiopharmaceutical program in any institutional practice or trial setting requires meticulous planning across several domains and seamless integration with oncology workflows for timely and accurate patient care.

This article explores the landscape, regulatory considerations, infrastructural and operational requirements along with future directions for expanding these therapies into clinical settings.

Current Landscape

Radiopharmaceuticals and theranostics have a rich history and promising applications for targeted therapies in oncology. As such, the global radiopharmaceuticals market has a projected compound annual growth rate (CAGR) of 9.8%, estimated to reach $19bn by 2035.1 Large pharma and biotechs alike are pushing innovation around radiopharmaceutical agents, with the recent development of more efficient alpha-emitting isotopes paving the way for new therapies.